What is the introduction and related background information of ibrutinib/Eco?

Ibrutinib/Ibrutinib, trade name Imbruvica (Imbruvica), is a BTK (Bruton tyrosine kinase) inhibitor that was first developed by Janssen Pharmaceuticals in the United States and was approved by the U.S. FDA in 2013. It is mainly used to treat a variety of B cell-related malignant tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), etc.

The mechanism of action of ibrutinib is to inhibit Bruton's tyrosine kinase (BTK), thereby blocking the B cell signaling pathway and reducing the proliferation of malignant B cells. This mechanism gives ibrutinib an important advantage in treating B-cell-derived cancers and avoids the extensive side effects of traditional chemotherapy drugs.

In** ibrutinib has become a standard treatment for chronic lymphocytic leukemia (CLL), providing an effective alternative especially for patients who cannot tolerate chemotherapy. For patients with mantle cell lymphoma (MCL), ibrutinib also shows good efficacy, especially when traditional treatments are ineffective, ibrutinib provides patients with new treatment hope. In addition, ibrutinib has also shown relatively ideal clinical effects in the treatment of Waldenstrom's macroglobulinemia (WM)** and other diseases.

The approval of ibrutinib allows patients to avoid many side effects of traditional chemotherapy drugs while controlling their disease for a long time. Its global launch not only changes the treatment landscape for B-cell cancers, but also provides clinicians with more treatment options. In China, ibrutinib was approved in 2017 and quickly entered clinical use.

The side effects of ibrutinib are mild. The most common side effects include mild gastrointestinal discomfort, infection, bleeding, etc., but the side effects are controllable in most patients. Compared with traditional chemotherapy, ibrutinib has significantly fewer side effects and the patient's quality of life has been significantly improved.

Reference materials:https://www.imbruvica.com/